Global Asthma Therapeutics Market to grow at a CAGR of 4.31% during 2016-2020: Key Vendors are GSK, Ivax, Merck, Invion, Amgen, Asmacure etc.

ResearchMoz added Latest Research Report titled " Global Asthma Therapeutics Market 2016-2020 " to it's Large Report database.

About Asthma Therapeutics

Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period.

Technavios analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=775675

Covered in this report
The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Breakthrough in asthma research
Asthma: An overview
PART 05: Pipeline portfolio
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Key buying criteria for asthma drugs
PART 08: Market segmentation by type of treatment
Preventive medications
Quick-relief medications
Others
PART 09: Market segmentation by drug class
Combination therapies
Bronchodilators
Immunosuppressants
Leukotriene antagonists
Mast cell stabilizers

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Global Asthma Therapeutics Market to grow at a CAGR of 4.31% during the period 2016-2020: Key Vendors GSK, Merck, Amgen, Asmacure, AstraZeneca

ResearchMoz added Latest Research Report titled " Global Asthma Therapeutics Market 2016-2020 " to it's Large Report database.

About Asthma Therapeutics

Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period.

Technavios analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=775675

Covered in this report
The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Breakthrough in asthma research
Asthma: An overview
PART 05: Pipeline portfolio
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Key buying criteria for asthma drugs
PART 08: Market segmentation by type of treatment
Preventive medications
Quick-relief medications
Others
PART 09: Market segmentation by drug class
Combination therapies
Bronchodilators
Immunosuppressants
Leukotriene antagonists
Mast cell stabilizers

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

ResearchMoz added Latest Research Report titled " Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations " to it's Large Report database.

GBI Research, a leading business intelligence provider, has released its latest research report,""Asthma Therapeutics in Major Developed Markets to 2020  Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations"".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=275426

Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 10
2.3 Etiology 11
2.4 Pathophysiology 12
2.5 Symptoms 12
2.6 Diagnosis 12
2.7 Assessment of Disease Severity 13
2.8 Treatment 15
2.9 Treatment Algorithm 16
2.10 Treatment Segments 18
2.10.1 ICS Monotherapy for the Maintenance Treatment of Asthma 19
2.10.2 Singulair (montelukast sodium) as First-Line Maintenance Therapy 21
2.10.3 ICS/LABA Combination Therapy 22
2.10.4 Add-on Therapies 27

3 Marketed Products 33
3.1 Overview 33
3.2 ICS for the Maintenance Treatment of Asthma 33
3.2.1 Arnuity (fluticasone furoate) - GSK 33
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma 34
3.3.1 Advair (fluticasone propionate and salmeterol xinafoate) - GSK 34
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma 35

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG